Targeting Angiogenesis in the Treatment of Multiple Myeloma

ISSN: 2211-5536 (Online)
ISSN: 2211-5528 (Print)


Volume 3, 4 Issues, 2014


Download PDF Flyer




Current Angiogenesis

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Dr. Dipak Panigrahy
The Center for Vascular Biology Research and The Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School
Boston, MA
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints


Targeting Angiogenesis in the Treatment of Multiple Myeloma

Author(s): Najib Dally and Elizabeth Eshel

Affiliation: Hematology Institute, Ziv Medical Center affiliated with the Faculty of Medicine in Zefat, Bar Ilan University, Zefat, Israel.

Abstract

Multiple Myeloma (MM) remains an incurable disease. Scientific understanding of the biology and influence of the microenvironment in disease progression and outcome has led to treatment improvements by targeting angiogenesis. Reviews of the underlying biology and meta-analyses of the clinical data tend to be mutually exclusive. This mini-review highlights important data regarding angiogenesis in MM as well as the drugs currently used to target angiogenesis in its treatment.

Keywords: Angiogenesis inhibitors, anti Angiogenetic agents, anti-angiogenic effects, immunomodulation, multiple myeloma

Purchase Online Rights and Permissions

Article Details

Volume: 2
First Page: 1
Last Page: 9
Page Count: 9
DOI: 10.2174/2211552802666140404003016
Advertisement

Related Journals



Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science